Get the Stockscreener App
0.871
1.05%
-0.0092
After Hours:
.88
0.009
+1.03%
Neurosense Therapeutics Ltd stock is traded at $0.871, with a volume of 243.57K.
It is down -1.05% in the last 24 hours and down -25.56% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.8802
Open:
$0.88
24h Volume:
243.57K
Relative Volume:
0.77
Market Cap:
$25.87M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.4909
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
+22.71%
1M Performance:
-25.56%
6M Performance:
-54.40%
1Y Performance:
-28.02%
1-Day Range:
$0.825
$0.90
1-Week Range:
$0.6801
$0.90
52-Week Range:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.871 | 26.14M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - Sahm
NeuroSense Unveils Favourable Safety Analysis Data Of PrimeC In NST-AD-001 Study For Alzheimer's - Nasdaq
NeuroSense Therapeutics (NASDAQ:NRSN) Receives Buy Rating from D. Boral Capital - Defense World
D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial - TipRanks
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile By Investing.com - Investing.com South Africa
Neurosense stock rises as Alzheimer’s drug shows favorable safety profile - Investing.com
Experimental Alzheimer's combo shows no serious side effects in trial - Stock Titan
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analysts2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
Forecast Cut: Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsBuy Signal & Daily Momentum Trading Reports - Улправда
Rally Mode: Is Capella Minerals Limited (N7D) stock worth buying before Fed actionEarnings Overview Summary & Safe Capital Investment Plans - moha.gov.vn
Will NeuroSense Therapeutics Ltd. stock pay special dividends2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
How NeuroSense Therapeutics Ltd. stock benefits from tech adoption2025 Volatility Report & Reliable Volume Spike Trade Alerts - Улправда
Is NeuroSense Therapeutics Ltd. stock resilient to inflationRate Hike & Weekly Momentum Stock Picks - Bölüm Sonu Canavarı
ETF Watch: Can NeuroSense Therapeutics Ltd. (H1Z) stock sustain institutional flowsJuly 2025 Recap & Fast Gain Swing Trade Alerts - DonanımHaber
How NeuroSense Therapeutics Ltd. (H1Z) stock compares with tech leaders2025 Stock Rankings & Low Volatility Stock Suggestions - Улправда
How NeuroSense Therapeutics Ltd. stock compares to growth peersJuly 2025 Technicals & AI Based Trade Execution Alerts - Улправда
It had formed inverted head and shoulders earlier soon it gave a break out of the pattern.2025 Historical Comparison & High Conviction Buy Zone Alerts - Bollywood Helpline
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requi - GuruFocus
Whale Trades: What dividend safety rating applies to NeuroSense Therapeutics Ltd H1Z stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation - MSN
Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell - Defense World
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc (LXRX) - setenews.com
NRSN: PARAGON phase III ALS trial starts mid-2026, with strong data, FDA clearance, and global scope - TradingView — Track All Markets
NRSN: Global phase III ALS trial set for mid-2026, with strong efficacy and active partnership talks - TradingView — Track All Markets
NeuroSense Completes Data Collection for Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) locks RoAD Phase 2 Alzheimer’s trial database, eyes Q1 2026 data - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser
How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq
NeuroSense Therapeutics LtdResuming regulatory advancement in Canada for PrimeC in amyotrophic lateral sclerosis - marketscreener.com
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks
Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView
Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser
How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser
NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan
NeuroSense Therapeutics (NRSN) Stock Analysis Report | Financials & Insights - Benzinga
What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser
Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ
Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt
Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn
NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):